Ori-CAR-002 / Oricell - LARVOL DELTA

Yuanqi Bio’s dual-target CAR-T preclinical data was presented at SITC Oral Presentation, and the abstract was selected into SITC TOP 100 [Google translation] (Sohu.com) - "Yuanqi Bio...announced that it will present its preclinical research data of the dual-target BCMAxGPRC5D CAR-T for heterogeneous multiple myeloma (MM) at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) held in Houston, Texas, USA on November 9, 2024. In addition, the preclinical data abstract was also selected as SITC TOP 100 abstracts...At this conference, Yuanqi Bio reported preclinical research data on BCMAxGPRC5D CAR-T therapy, with the following highlights: The anti-tumor activity was significantly enhanced, outperforming single-antigen CAR-T therapy in preclinical models and effectively eliminating multiple myeloma cells; This enables CAR-T cells to expand better and persist under the pressure of high tumor load; It effectively addresses the problem of antigen loss and still has killing activity against any tumor cell that escapes the tumor antigen, thus overcoming the limitations of single antigen therapy."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

Strategic optimization of BCMA and GPRC5D dual-targeted CAR T cells for heterogeneous multiple myeloma (SITC 2024) - "GPRC5D CAR-T cells have mitigated BCMA escape-mediated relapse in murine models, thereby demonstrating their potential in addressing this clinical challenge...1S cells at an E:T ratio of 1:1Download figure Open in new tab Download powerpoint Abstract 267 Figure 3 OriCAR002 T cells exhibited superior functional advantage in vitro...(B) Theoretical single combination pattern of the an- ti-GPRC5D VHH and GPRC5D on MM cells. (C) Theo- retical double-binding pattern of the bispecifc Ori- CAR002 to BCMA and GPRC5D on MM cells"

CAR T-Cell Therapy • Heterogeneity • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • GPRC5D

Strategic optimization of BCMA and GPRC5D dual-targeted CAR T cells for heterogeneous multiple myeloma (SITC 2024) - "GPRC5D CAR-T cells have mitigated BCMA escape-mediated relapse in murine models, thereby demonstrating their potential in addressing this clinical challenge...1S cells at an E:T ratio of 1:1Download figure Open in new tab Download powerpoint Abstract 267 Figure 3 OriCAR002 T cells exhibited superior functional advantage in vitro...(B) Theoretical single combination pattern of the an- ti-GPRC5D VHH and GPRC5D on MM cells. (C) Theo- retical double-binding pattern of the bispecifc Ori- CAR002 to BCMA and GPRC5D on MM cells"

CAR T-Cell Therapy • Heterogeneity • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • GPRC5D

Strategic optimization of BCMA and GPRC5D dual-targeted CAR T cells for heterogeneous multiple myeloma (SITC 2024) - "GPRC5D CAR-T cells have mitigated BCMA escape-mediated relapse in murine models, thereby demonstrating their potential in addressing this clinical challenge...1S cells at an E:T ratio of 1:1Download figure Open in new tab Download powerpoint Abstract 267 Figure 3 OriCAR002 T cells exhibited superior functional advantage in vitro...(B) Theoretical single combination pattern of the an- ti-GPRC5D VHH and GPRC5D on MM cells. (C) Theo- retical double-binding pattern of the bispecifc Ori- CAR002 to BCMA and GPRC5D on MM cells"

CAR T-Cell Therapy • Heterogeneity • IO biomarker • Hematological Malignancies • Multiple Myeloma • Oncology • GPRC5D